« Back
Home /
Pazopanib

Pazopanib

Item no.	M1842-1g
Manufacturer	AbMole
CASRN	444731-52-6
Amount	1g
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Renal Cancer
Type	Inhibitors
Specific against	other
Purity	>99.0%
Citations	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma. Sparidans, et al . J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 10. PMID: 22917595 . Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Zivi, et al . Expert Opin Drug Saf. 2012 Sep,11(5):851-9. PMID: 22861374 . Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Necchi, et al . Lancet Oncol. 2012 Aug,13(8):810-6. PMID: 22819172 . Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Sleijfer, et al . Br J Cancer. 2012 Aug 7,107(4):639-45. PMID: 22805326 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GW786034
Similar products	Pazopanib, GW786034
Available
Target Information	VEGFR/PDGFR
Molecular Weight	437, 52
Solubility	DMSO 62 mg/mL
Bioactivity information	Pazopanib is an oral angiogenesis inhibitor of tyrosine kinases, targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1842-1g-safety-datasheet.pdf